News | January 29, 2023
Vimta Labs reports Q3 FY23 consolidated PAT at Rs. 10.24 Cr
The company has reported total income of Rs. 78.50 crores during the period ended December 31, 2022
The company has reported total income of Rs. 78.50 crores during the period ended December 31, 2022
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
The company has reported total income of Rs. 211.36 crores during the period ended December 31, 2022
The company will engage with the agency to resolve the import alert at the earliest.
The company has reported total income of Rs. 6848.5 crores during the period ended December 31, 2022
The company has reported total income of Rs. 2481 crores during the period ended December 31, 2022
Cell sorting technology supports researchers advancing new therapies
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
Medical Tourism will boost India’s economy
The company is adding new capabilities of Combi-line for Microsphere, additional Bag line and lyos for the Penem block in Pashamylaram facility in Hyderabad and will be earmarking capital for further building on its Biosimilar CDMO facility
Subscribe To Our Newsletter & Stay Updated
